ADVENTRX first one fourth net loss increases to $4.

Lauderdale, Miami and Jacksonville, eight AHF Pharmacies located through the entire continuing state, a statewide disease management program; and its Positive Healthcare Managed Treatment program.. ADVENTRX first one fourth net loss increases to $4.2M ADVENTRX Pharmaceuticals, Inc. today reported financial results for the initial quarter ended March 31, 2012. In the first quarter, we focused our resources on ANX-188, including manufacturing activities related to generating clinical trial material for our planned phase 3 study in individuals with sickle cell disease, stated Brian M. Culley, CEO of ADVENTRX. First Quarter 2012 Operating Results ADVENTRX’s net loss relevant to common share for the first quarter of 2012 was $4.2 million, or $0.09 per share , compared to a net reduction applicable to common stock of $3.0 million, or $0.13 per share , for the same period in 2011.2 million, a rise of $1.6 million, or 262 percent, in comparison to $0.6 million for the same period in 2011.‘Williams syndrome presents a unique lens for finding the how genes type the brain circuitry in charge of human behavior,’ explains Korenberg. This prompted Korenberg’s collaboration with Bellugi, who’s thinking about the cognitive areas of the disorder, ‘Genetic contributions to individual cognition and behavior are clear but difficult to define,’ says Bellugi. Virtually everyone with Williams Syndrome offers exactly the same group of genes lacking . There also are rare cases of people who retain a number of genes that most people with the disorder have dropped.